Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 8/20 | 0.61 |
| ▸ | CDK9 | P50750 | 8/20 | 0.61 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.61 |
| ▸ | INSR | P06213 | 2/20 | 0.61 |
| ▸ | MET | P08581 | 2/20 | 0.61 |
| ▸ | CDC7 | O00311 | 1/20 | 0.61 |
| ▸ | PLK4 | O00444 | 1/20 | 0.61 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.61 |
| ▸ | AURKA | O14965 | 1/20 | 0.61 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.61 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.61 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.61 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.61 |
| ▸ | JAK2 | O60674 | 1/20 | 0.61 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.61 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.61 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.61 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.61 |
| ▸ | PAK4 | O96013 | 1/20 | 0.61 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29904751 | 1.00 | CDK7 (0.61) | CDK7CDK9ALKINSRMET | |
| Benzamide SCHEMBL2061396 | 0.89 | ALK (0.52) | CDK7CDK9ALKINSRMET | |
| SCHEMBL12856163 | 0.87 | ALK (0.51) | CDK7CDK9ALKINSRMET | |
| SCHEMBL4101888 | 0.87 | CDK7 (0.59) | CDK7CDK9ALKINSRMET | |
| SCHEMBL12780295 | 0.87 | ALK (0.48) | CDK7CDK9ALKINSRMET | |
| SCHEMBL375360 | 0.87 | ZAP70 (0.61) | CDK7CDK9ALKINSRMET | |
| SCHEMBL12570609 | 0.87 | ALK (0.67) | CDK7CDK9ALKINSRMET | |
| SCHEMBL31512671 | 0.86 | ALK (0.71) | CDK7CDK9ALKINSRMET | |
| SCHEMBL2061222 | 0.86 | ALK (0.71) | CDK7CDK9ALKINSRMET | |
| SCHEMBL375081 | 0.86 | ALK (0.52) | CDK7CDK9ALKINSRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228458-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | THERAPEX CO., LTD. (KR) | 2024-07-11 | — | — | US | disclosed |
| EP-4286376-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | Therapex Co., Ltd. (KR) | 2023-12-06 | — | — | EP | disclosed |
| CN-117120424-A | Pyrimidine derivatives having protein kinase inhibitory activity and therapeutic combinations comprising the same | 泰拉佩克斯有限公司 | 2023-11-24 | — | — | CN | disclosed |
| WO-2023134582-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 上海立森印迹医药技术有限公司 | 2023-07-20 | — | — | WO | disclosed |
| WO-2023134582-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 上海立森印迹医药技术有限公司 | 2023-07-20 | — | — | WO | disclosed |
| CN-116444488-A | Pyrimidine-2, 4-diamine derivative and preparation method and application thereof | 上海立森印迹医药技术有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20230165857-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | SUMITOMO PHARMA ONCOLOGY, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230165857-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | SUMITOMO PHARMA ONCOLOGY, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20210205304-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-07-08 | — | — | US | disclosed |
| US-11013741-B1 | AXL kinase inhibitors and use of the same | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20060247241-A1 | 2,4-Di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | NOVARTIS AG (CH) | 2006-11-02 | — | — | US | disclosed |
| EP-1660458-A1 | 2, 4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | Novartis AG (CH) | 2006-05-31 | — | — | EP | disclosed |
| EP-1606265-A1 | 2, 4- DI (PHENYLAMINO) PYRIMIDINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | Novartis AG (CH) | 2005-12-21 | — | — | EP | disclosed |
| WO-2005016894-A1 | 2, 4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2005-02-24 | — | — | WO | disclosed |
| WO-2004080980-A1 | 2, 4- DI (PHENYLAMINO) PYRIMIDINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | ALK, MET, RET | CDK7 570/4885CDK9 539/4885ALK 1/4885 |
| US-11013741-B1 | AXL kinase inhibitors and use of the same | AXL, FLT3, TEC | CDK7 451/4885CDK9 466/4885ALK 18/4885 |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | TYMS, TYMP, DPYD | CDK7 284/4885CDK9 379/4885ALK 3200/4885 |
| US-20240228458-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | EGFR, ERBB2, ERBB3 | CDK7 332/4885CDK9 23/4885ALK 120/4885 |
| US-20210205304-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | AXL, FLT3, TEC | CDK7 445/4885CDK9 467/4885ALK 17/4885 |
| US-20230165857-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | AXL, FLT3, TEC | CDK7 474/4885CDK9 476/4885ALK 23/4885 |
| US-20060247241-A1 | 2,4-Di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | TYMS, UMPS, TYMP | CDK7 343/4885CDK9 455/4885ALK 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.